MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its division for research and diagnostic antibodies, AbD Serotec, will launch a series of novel anti-drug antibodies (ADAs) to strengthen its position as a leading provider of diagnostic reagents. Starting with the recent launch of fully human, recombinant antibodies binding Rituximab (Rituxan®) and Trastuzumab (Herceptin®), AbD Serotec plans to expand this product category with antibodies against Alemtuzumab (Campath®), Bevacizumab (Avastin®), Infliximab (Remicade®), Ustekinumab (Stelara®), and Adalimumab (Humira®) in the near future.* Other anti-drug antibodies can be requested as part of the custom antibody service of AbD Serotec.
"Anti-drug antibodies are ideal for preclinical and clinical research to support the development of novel antibody drugs as well as biosimilars," commented Dieter Feger, Head of AbD Serotec. "We see an increasing demand for these tools from clinical research organizations, biopharmaceutical and pharmaceutical companies. Due to the recombinant nature of our HuCAL technology, AbD Serotec is able to deliver an unlimited, secure and batch to batch consistent supply of these assay reagents for extensive clinical studies."
The Human Combinatorial Antibody Library can deliver highly specific, high-affinity monoclonal antibodies against any given antibody drug with unprecedented success rates. The highly specific HuCAL ADAs are developed solely in vitro, pre-adsorbed against any available controls and human serum. An option to screen for inhibiting or neutralizing antibodies is also offered. An unlimited, consistent supply eliminates the need for revalidation of new sources in extensive clinical studies. Other advantages include the possibility to convert selected ADAs into various other human isotypes and Ig subclasses. This provides customers with a single antibody solution for both immune response and pharmacokinetic assays ultimately saving assay development resources.
* Not all anti-drug antibodies might be available in all countries